A5090108117- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Fibroblast Growth Factor Research
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Brain Metastases and Treatment
- Cancer, Hypoxia, and Metabolism
- Kruppel-like factors research
- Statistical Methods in Clinical Trials
- Chronic Lymphocytic Leukemia Research
- Melanoma and MAPK Pathways
- Breast Lesions and Carcinomas
- Metabolism, Diabetes, and Cancer
- Metastasis and carcinoma case studies
- Medical Imaging Techniques and Applications
MedSIR (Spain)
2013-2025
Universidad Europea
2025
Universidad de Málaga
2025
Vall d'Hebron Institute of Oncology
2012-2024
International Breast Cancer Study Group
2020-2024
Asociación Española Contra el Cáncer
2024
INCLIVA Health Research Institute
2024
Centro de Investigación Biomédica en Red de Cáncer
2024
Hospital Clínico Universitario de Valencia
2024
Instituto Oncológico Dr. Rosell
2020-2023
In an interim analysis of this phase 3 trial, the addition pembrolizumab to chemotherapy resulted in longer progression-free survival than alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) a combined positive score (CPS; number PD-L1–staining tumor cells, lymphocytes, and macrophages, divided by total viable multiplied 100) 10 or more. The results final overall have not been reported.
Inhibition of the PI3K/AKT pathway results in induction ER-dependent transcriptional activity and susceptibility to anti-estrogen therapy ER-positive breast cancer.
MAPK and PI3K/AKT/mTOR pathways play important roles in many tumors. In this study, safety, antitumor activity, pharmacokinetics of buparlisib (pan class PI3K inhibitor) trametinib (MEK were evaluated.This open-label, dose-finding, phase Ib study comprised dose escalation, followed by expansion part patients with RAS- or BRAF-mutant non-small cell lung, ovarian, pancreatic cancer.Of note, 113 enrolled, 66 47 dose-escalation -expansion parts, respectively. MTD was established as 70 mg + 1.5...
Fibroblast growth factor receptor 1 (FGFR1) and FGFR2 amplifications are observed in approximately 10% of breast cancers related to poor outcomes. We evaluated whether dovitinib (TKI258), an inhibitor FGFR1, FGFR2, FGFR3, presented antitumor activity FGFR-amplified cancers.Preclinical was both cancer cell lines FGFR1-amplified xenograft model (HBCx2). Dovitinib then a phase II trial that included 4 groups patients with human EGF 2-negative metastatic on the basis FGFR1 amplification hormone...
Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy not yet been evaluated active brain metastases (BMs). DEBBRAH aims to assess T-DXd or HER2-low ABC and central nervous system involvement.This ongoing, five-cohort, phase II study (NCT04420598) enrolled stable, untreated, progressing BMs, and/or leptomeningeal carcinomatosis. Here, we report findings from non-progressing BMs after local...
1001 Background: Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) in combination with ET has become a standard first-line treatment for pts endocrine-sensitive, HR[+]/HER2[-] ABC. The optimal after progression on CDK4/6i remains unknown. This study aims to determine if P maintenance an alternative improves the antitumor activity of second-line this patient population. Methods: A total 198 ABC who had disease plus (aromatase inhibitor or fulvestrant) were included. Pts eligible they...
// Leticia De Mattos-Arruda 1, * , Giulia Bottai 2, Paolo G. Nuciforo 3 Luca Di Tommaso 4 Elisa Giovannetti 5, 6 Vicente Peg 7 Agnese Losurdo 8 José Pérez-Garcia 1 Giovanna Masci Fabio Corsi 9 Javier Cortés 10 Joan Seoane 11 George A. Calin 12, 13 Libero Santarpia 2 Vall d'Hebron Institute of Oncology, University Hospital, Universitat Autònoma de Barcelona, Spain Oncology Experimental Therapeutics Unit, IRCCS Humanitas Clinical and Research Institute, Rozzano, Milan, Italy Molecular Group,...
The PI3K signaling pathway regulates diverse cellular processes, including proliferation, survival, and metabolism, is aberrantly activated in human cancer. As such, numerous compounds targeting the are currently being clinically evaluated for treatment of cancer, several have shown some early indications efficacy breast However, resistance against these agents, both de novo acquired, may ultimately limit compounds. Here, we taken a systematic functional approach to uncovering potential...
The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer. Meanwhile, the antiestrogen fulvestrant was shown to be superior anastrozole absence of inhibition this patient population.To assess whether is when combined scenario.In international, randomized, open-label, phase 2 clinical study conducted from July 30, 2015,...
Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of may more accurately identify breast cancer (BC) patients who will respond treatments.Using selected reaction monitoring mass spectrometry (SRM-MS), we quantified protein levels in formalin-fixed, paraffin-embedded (FFPE) tissue samples that had been classified as 0, 1+, 2+ or 3+...
Clinical experience increasingly suggests that molecular prescreening and biomarker enrichment strategies in phase I trials with targeted therapies will improve the outcomes of patients cancer. In keeping exigencies a personalized oncology program, tumors from advanced chemorefractory colorectal cancer were analyzed for specific aberrations (KRAS/BRAF/PIK3CA mutations, PTEN pMET expression). Patients subsequently offered matched agents (MTA) directed at identified anomalies. During 2010...
Abstract Background Eribulin, a nontaxane synthetic inhibitor of microtubule dynamics, is widely used to manage locally advanced or metastatic breast cancer (MBC). Eribulin has demonstrated immunomodulatory activity on the tumour microenvironment. Baseline neutrophil-to-lymphocyte ratio (NLR), marker immune status, may predict progression-free survival in eribulin treatment. This post hoc analysis assessed predictors for overall (OS). Methods The phase 3 open-label study (EMBRACE) versus...
// Begoña Martin-Castillo 1, * , Sonia Pernas 2, Joan Dorca 3 Isabel Álvarez 4, 5 Susana Martínez 6 Jose Manuel Pérez-Garcia 7 Norberto Batista-López 8 César A. Rodríguez-Sánchez 9, 10 Kepa Amillano 11 Severina Domínguez 12 Maria Luque 13 Agostina Stradella 2 Idoia Morilla Gemma Viñas Javier Cortés 14 Elisabet Cuyàs 15 Sara Verdura Álvaro Fernández-Ochoa 16, 17 Salvador Fernández-Arroyo 18 Antonio Segura-Carretero Jorge Joven Elsa Pérez 19 Neus Bosch 20 Margarita Garcia 21 Eugeni López-Bonet...